Return On Equity
-67%
Trailing 12 months · Through 30 Sep 2022
YoY relative change: -623%
Period Q3 2022 · Filed 22 Nov 2022
Return On Equity
-67%
Trailing 12 months · Through 30 Sep 2022
YoY relative change: -623%
Return On Assets
4.8%
Trailing 12 months · Through 30 Sep 2022
YoY relative change: -533%
Current Ratio
0.03x
Period-end balance · Through 30 Sep 2022
YoY relative change: -99%
Debt-to-equity
-1.01x
Period-end balance · Through 30 Sep 2022
YoY relative change: -36%
| Metric | Latest value | YoY relative change |
|---|---|---|
| Return On Equity |
-67%
Trailing 12 months · 30 Sep 2022
|
-623% |
| Return On Assets |
4.8%
Trailing 12 months · 30 Sep 2022
|
-533% |
| Metric | Latest value | YoY relative change |
|---|---|---|
| Current Ratio |
0.03x
Period-end balance · 30 Sep 2022
|
-99% |
| Debt-to-equity |
-1.01x
Period-end balance · 30 Sep 2022
|
-36% |
| Metric | Latest value | YoY relative change |
|---|---|---|
| Net Income (Loss) Attributable to Parent |
$10,983,949
Trailing 12 months · 30 Sep 2022
|
| Metric | Latest value | YoY relative change |
|---|---|---|
| Common Stock, Value, Issued |
$575
Period-end balance · 30 Sep 2022
|
0% |
These supporting metrics stay fully source-backed for deeper research. Scan the latest value and reported period first, then open a metric page when you need the full filing trail.
| Metric | Latest value | YoY relative change |
|---|---|---|
| Assets |
$231,389,235
Period-end balance · 30 Sep 2022
|
+0.3% |
| Assets, Current |
$95,252
Period-end balance · 30 Sep 2022
|
-86% |
| Cash and Cash Equivalents, at Carrying Value |
$13,145
Period-end balance · 30 Sep 2022
|
-97% |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents |
$13,145
Period-end balance · 30 Sep 2022
|
-97% |
| Liabilities |
$13,215,210
Period-end balance · 30 Sep 2022
|
-36% |
| Liabilities and Equity |
$231,389,235
Period-end balance · 30 Sep 2022
|
+0.3% |
| Liabilities, Current |
$3,517,792
Period-end balance · 30 Sep 2022
|
+881% |
| Operating Income (Loss) |
-$4,363,031
Trailing 12 months · 30 Sep 2022
|
-4831% |
| Preferred Stock, Par or Stated Value Per Share |
0
Period-end balance · 30 Sep 2022
|
0% |
| Preferred Stock, Shares Authorized |
5,000,000
Period-end balance · 30 Sep 2022
|
0% |
| Retained Earnings (Accumulated Deficit) |
-$13,120,533
Period-end balance · 30 Sep 2022
|
+34% |
| Stockholders' Equity Attributable to Parent |
-$13,119,958
Period-end balance · 30 Sep 2022
|
+34% |
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open metric pages to inspect the reported history.
Company facts change as new 10-Q and 10-K filings update the latest reported period, headline values, and cross-company comparison context.
Freshness comes from the latest SEC company facts period available for this filer and the linked metric history pages.
Latest update
Latest financial period: Q3 2022. Reopen this facts page to verify the newest reported period against the prior baseline.
Update date
22 Nov 2022
Page type
Company facts
Latest period
Q3 2022
SEC-backed company facts were refreshed from filings filed on 22 Nov 2022.
Benchmark Context
Return On Equity is down about 623% versus the comparable prior period.
Compared with
Compared with Biotech Acquisition Co's recent history first. Same-industry peer context appears only when enough SEC-backed benchmark coverage exists.
Why this is notable
Return On Equity already has a self-history signal here, but same-industry benchmark context waits until the benchmark sample is strong enough.
Industry benchmark context uses SEC-reported values from the same methodology version. Latest periods may differ across companies.
Based on company facts extracted from SEC 10-Q/10-K XBRL filings where available. Open company facts to inspect the reported metric history.
Latest financial snapshot (2022-09-30) highlights Return On Equity -66.6%, Return On Assets 4.8%, and Current Ratio 0.03x.
SEC-only DCF estimate using a normalized free cash flow base, cash, debt, and reported share count when available.
USD inputs only. Cash and complete debt must share the latest balance date. Missing balances are unknown, never zero; equity value and market EV remain unavailable until both are verified.
Equity value = DCF enterprise value + cash − debt. Cash flow uses matching annual or trailing-12-month periods.
Transparent 0-100 scoring model based on profitability, financial health, and growth factors.
8.0/100
Weak Confidence low
-67%
Metric score 0.0/100
4.8%
Metric score 34.4/100
No strong signals yet.
Return On Equity, Return On Assets, and Current Ratio
This score is transparent and deterministic. We weight profitability, financial health, and growth metrics, then renormalize weights when SEC data is missing.
| Metric | Weight | V1 threshold |
|---|---|---|
| ROIC | 20 | 5% to 20% |
| ROE | 15 | 8% to 25% |
| ROA | 10 | 2% to 10% |
| Operating Margin | 5 | 5% to 25% |
| Current Ratio | 12 | 1.0x to 2.0x |
| Quick Ratio | 8 | 0.8x to 1.5x |
| Debt to Equity | 10 | 0.3x to 2.0x (lower is better) |
| Revenue YoY | 10 | -10% to +20% |
| Net Income YoY | 10 | -10% to +20% |
Metrics are computed with a market-consensus convention designed for cross-portal comparability.
CIK / security context first